Nu-Med Plus, Inc. NUMD

Company Overview

Nu-Med Plus, Inc. (OTC: NUMD) is a U.S.-based healthcare and medical technology company focused on the development of nitric oxide delivery technologies and related therapeutic applications. The company operates primarily within the biotechnology, medical device, and respiratory care industries, with a strategic emphasis on inhaled nitric oxide therapies designed for emergency medicine, infectious disease response, and pulmonary health applications. Public disclosures indicate that the company’s core intellectual property and commercialization efforts center on nitric oxide generation and delivery systems intended to provide alternatives to conventional compressed gas-based nitric oxide solutions.

The company’s primary business activities have included the development of portable nitric oxide generation technologies and related treatment systems, particularly through its subsidiary structure and affiliated intellectual property arrangements. Nu-Med Plus has publicly discussed applications involving respiratory illnesses, emergency response environments, and military or remote-use medical scenarios. Historically, the company evolved from a broader healthcare-focused business into a more specialized medical technology developer centered on nitric oxide therapeutics and associated delivery platforms. Available public filings and OTC market disclosures indicate that commercialization activities have remained developmental in nature, with limited reported operating revenue relative to research and technology advancement efforts.